<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685317</url>
  </required_header>
  <id_info>
    <org_study_id>19-002836</org_study_id>
    <nct_id>NCT04685317</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation</brief_title>
  <official_title>A Pilot Randomized Study of the Use of The Sentinel Device for Cerebral Protection During Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malini Madhavan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent&#xD;
      occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary&#xD;
      purpose of this study is to study if cognitive function after AF ablation differs between&#xD;
      those treated with the Sentinel cerebral protection device and those who do not receive the&#xD;
      device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If assigned to receive the device, the Sentinel® Cerebral Protection System will be placed in&#xD;
      your heart at the beginning of your ablation procedure, and then removed along with any&#xD;
      collected blood debris upon completion of your procedure. The study team will then call you&#xD;
      30 days after your procedure to assess any neurological events. Your final visit will be 90&#xD;
      days after your procedure to complete a second 30 minute session of cognitive testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized study of Sentinel cerebral protection device vs no cerebral protection device in patients undergoing atrial fibrillation ablation.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident of stroke / TIA 7 days post AF ablation</measure>
    <time_frame>7 days post AF ablation</time_frame>
    <description>Incidence of stroke / TIA confirmed using physical examination and / or brain imaging during or within 7 days of the AF ablation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident of stroke / TIA 90 days post AF ablation</measure>
    <time_frame>90 days post AF ablation</time_frame>
    <description>Incidence of stroke / TIA during or within 90 days of the AF ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neurocognitive function score</measure>
    <time_frame>Baseline, 90 days</time_frame>
    <description>Montreal cognitive assessment will administered at baseline and 90 days following ablation. Change in cognitive function score will be compared between the groups. The score ranges from 0 to 30 with higher score indicating better cognitive performance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sentinel® Cerebral Protection System Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentinel® Cerebral Protection System</intervention_name>
    <description>A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.</description>
    <arm_group_label>Sentinel® Cerebral Protection System Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men / women over the age of 18 years undergoing radiofrequency or cryo-balloon&#xD;
             ablation for AF in accordance with the current AHA/ACC/HRS guideline for management of&#xD;
             patients with atrial fibrillation. This includes patients with symptomatic paroxysmal,&#xD;
             persistent or long-standing persistent AF not responsive to or intolerant of a Class I&#xD;
             or III anti-arrhythmic drug or patients with symptomatic paroxysmal or persistent AF&#xD;
             prior to the initiation of a Class I or Class III antiarrhythmic drug). The decision&#xD;
             to perform catheter ablation for AF will be made by the treating provider and the&#xD;
             patient in accordance with the guidelines noted above. (January et al. J Am Coll&#xD;
             Cardiol vol. 64, No. 21, 2014, page e1)&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
          -  Patients should have acceptable aortic arch anatomy and vessel diameters without&#xD;
             significant stenosis as assessed using pre-procedure CT angiogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anatomy unsuitable for use of Sentinel device:&#xD;
&#xD;
               -  Right extremity vasculature not suitable due to compromised arterial blood flow.&#xD;
&#xD;
               -  Brachiocephalic, left carotid or aortic arch not suitable due to excessive&#xD;
                  tortuosity, significant ectasia, stenosis (&gt;70%), dissection or aneurysm.&#xD;
&#xD;
          -  Cerebrovascular accident or transient ischemic attack within six months&#xD;
&#xD;
          -  Carotid disease requiring treatment within six weeks&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Known history of dementia.&#xD;
&#xD;
          -  Known hypersensitivity to nickel-titanium.&#xD;
&#xD;
          -  Presence of MRI non-compatible implanted devices including cardiac implantable&#xD;
             electronic devices.&#xD;
&#xD;
          -  The presence of left atrial thrombus. All patients routinely undergo transesophageal&#xD;
             echocardiogram prior to ablation and / or intra-cardiac echocardiogram at the&#xD;
             beginning of the ablation procedure to rule out the presence of left atrial thrombus.&#xD;
&#xD;
          -  Patients with a reversible cause for AF such as hyperthyroidism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malini Madhavan, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Hughes-Borst</last_name>
    <phone>507-528-6123</phone>
    <email>Hughes-Borst.Becky@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Malini Madhavan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

